Yao Fu

Dr. Yao Fu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
CLChang Liu
Chang Liu
XLXuanqi Liu
Xuanqi Liu
YWYujiao Wang
Yujiao Wang
HYHonghong Yu
Honghong Yu
QLQi Li
Qi Li
LSLingyun Sun
Lingyun Sun

25 November 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MLMengmeng Li
Mengmeng Li
XZXiaoya Zhao
Xiaoya Zhao
JWJun Wu
Jun Wu
SZShimeng Zhou
Shimeng Zhou
YFYao Fu
Yao Fu
SWShouyu Wang
Shouyu Wang
Despite overexpression of N-acetyltransferase 10 (NAT10) in colorectal cancer (CRC), its immunomodulatory role in the tumor microenvironment remains elusive. Here, we reveal that NAT10 promotes immune evasion through N4-acetylcytosine–dependent (ac4C-dependent) mRNA stabilization. Using syngeneic mouse models (MC38/CT-26), intestinal epithelial-cell specific Nat10 conditional KO ( Nat10 cKO ) mice, patient-derived organoids, and clinical specimens, we show that Nat10 ablation enhanced CD8 + T cell–mediated antitumor immunity. Single-cell RNA-seq revealed increased cytotoxic CD8 + T cell infiltration in Nat10 cKO tumors, which was corroborated by the inverse correlation of tumoral NAT10 expression and CD8 + T cell number in clinical specimens. Multi-omics integration analysis identified DKK2 as the predominant NAT10-regulated transcript. NAT10 stabilized DKK2 mRNA via ac4C modification, leading to high expression of the DKK2 protein. Secreted DKK2 engaged LRP6 receptors to activate AKT-mTOR signaling, inducing cholesterol accumulation in CD8 + T cells and impairing their cytotoxicity. Pharmacological NAT10 inhibition (Remodelin treatment) or DKK2 neutralization restored CD8 + T cell function and synergized with anti–PD-1 therapy. Our findings establish the NAT10/DKK2/LRP6/AKT-mTOR/cholesterol axis as a critical regulator of CD8 + T cell dysfunction in CRC, positioning NAT10/DKK2 as a potential target to enhance immunotherapy efficacy.

14 July 2023 in Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
XPXiaohong Pu
Xiaohong Pu
YFYao Fu
Yao Fu
QSQi Sun
Qi Sun
LLLin Li
Lin Li
AKAttigah Kwasi
Attigah Kwasi
BSBeicheng Sun
Beicheng Sun
Aims Currently, the clinicopathological characteristics of gastric cancer (GC) with oncogenic NTRK alterations are not well known. Although NTRK fusion has been identified as prevalent in DNA mismatch repair protein deficient (dMMR) colorectal cancer (CRC), the relationship between NTRK alterations and dMMR protein expression in GC has not been previously explored. Methods: Our study comprised 51 cases of EBV(Epstein-barr virus)-associated gastric carcinomas, 94 cases of dMMR GC, 90 cases of gastric adenocarcinoma with hepatoid or enteroblastic differentiation (GAHED) and 256 cases of conventional GC. Furthermore, to investigate the connection between NTRK fusion and dMMR proteins, we collected dMMR tumours of various types, including 21 cases of duodenal adenocarcinomas, 46 endometrioid carcinomas and 82 CRCs. NTRK fusion and amplification were screened in GC and various types of dMMR tumours using fluorescence in situ hybridisation (FISH), while cases positive for FISH translocation underwent next-generation sequencing testing. Results: Our findings revealed the existence of two cases each of NTRK fusions and NTRK amplifications, which were all enriched in case of GAHED. Additionally, following an analysis of several types of cancers, we discovered that NTRK gene alterations were only present in dMMR CRC. Conclusions: Our results indicate that NTRK gene alterations are not enriched in GC with dMMR but are specifically enriched in cases of GAHED.

12 November 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
WWWeibo Wang
Weibo Wang
SYShuiping Yin
Shuiping Yin
DXDandan Xu
Dandan Xu
STSupeng Tai
Supeng Tai
XCXi Cheng
Xi Cheng
JZJun Zhou
Jun Zhou
SMARCA4-deficient tumors represent a highly aggressive subtype of malignancy defined by the loss of SMARCA4 expression, and are associated with rapid progression and poor prognosis. We report the first documented case of SMARCA4-deficient renal cell carcinoma (RCC) in an adult (pT3aN1M1, Stage IV), characterized by sarcomatoid and rhabdomyoblastic differentiation, aggressive clinical behavior, and resistance to standard systemic therapies. This case provides a comprehensive analysis of clinical, pathological, imaging, and genetic findings, offering insights to refine diagnostic, therapeutic, and preventive strategies for this rare malignancy.

8 October 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
XCXi Cheng
Xi Cheng
WWWeibo Wang
Weibo Wang
LYLexing Yang
Lexing Yang
STSupeng Tai
Supeng Tai
JTJunyue Tao
Junyue Tao
JZJun Zhou
Jun Zhou
Primary bladder mucinous adenocarcinoma (BMA) is an exceedingly rare and aggressive malignancy. We report a case of a 72-year-old male presenting with hematuria and dysuria. Imaging revealed a bladder mass, and histopathological examination following biopsy demonstrated characteristic extracellular mucin pools and signet-ring cells. Immunohistochemistry (IHC) was crucial for diagnosis, showing a negative profile for GATA binding protein 3 (GATA3) and Special AT-rich sequence-binding protein 2 (SATB2), along with membrane nuclear positivity for β-catenin. Endoscopic examination confirmed the absence of a primary gastrointestinal malignancy. The patient underwent robot-assisted laparoscopic radical cystoprostatectomy followed by three cycles of adjuvant chemotherapy with the FOLFOX regimen (5-fluorouracil, leucovorin, and oxaliplatin). No recurrence was observed during the 6-month follow-up. This case highlights the diagnostic challenges of BMA and emphasizes the importance of a multimodal diagnostic approach incorporating histopathology, immunohistochemistry, and endoscopy. The potential efficacy of adjuvant FOLFOX regimen is worth further exploration given the lack of standard therapeutic guidelines for this rare entity.

7 April 2022 in Research Square
Verified
Preprint
Open access
PDF file
JWJianjun Wang
Jianjun Wang
NSNa Shi
Na Shi
FNFengnan Niu
Fengnan Niu
YFYao Fu
Yao Fu
XFXiangshan Fan
Xiangshan Fan
Background Hepatoid adenocarcinoma of bladder (HACD) is extremely rarely reported. Only 10 cases of HACD have been reported to date in English literature and no molecular analyses of HACD have ever been reported Case presentation: This case was a 57-year-old man who complained of gross hematuria for 5 days and urinary tract ultrasound examination revealed a hypoechoic mass at the right lateral wall of the bladder. 10 months later, the tumor recurred and transurethral resection was performed again. Definitive diagnosis of HACD was made by morphological and immunohistochemical analysis. A comparison was made between those two resections by the next generation sequencing (NGS). Somatic mutations of TP53, RB1 and KMT2D and amplifications of CCND1 and FGFR1 were identified in both resections. FGFR3 amplification was detected in the recurrent resection. Conclusions Detection of amplifications of FGFR1 and FGFR3 suggests that the FGFR pathway may play an important role in HACD and could be a candidate for personalized treatment. In this report, we provide some useful molecular clues to the analysis of HACD, while the mechanism and treatment still need to be explored.